Last reviewed · How we verify

NCT06993948

Hyperdynamic Left Ventricular Ejection Fraction as a Predictor of Mortality in Intensive Care Unit Patients With Septic Shock

Completed Last updated 29 May 2025
What this trial tests

trial testing Transthoracic echocardiography in Hyperdynamic in 235 participants. Completed in 1 July 2023.

Timeline
1 August 2022
Primary endpoint
1 July 2023
1 July 2023

Quick facts

Lead sponsorAin Shams University
StatusCompleted
Study typeOBSERVATIONAL
Enrollment235
Start date1 August 2022
Primary completion1 July 2023
Estimated completion1 July 2023
Sites1 location across Egypt

Drugs / interventions tested

Conditions studied

Sponsor

Ain Shams University

Who can join

18 and older, any sex, with Hyperdynamic or Left Ventricular Ejection Fraction. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study aimed to evaluate the cause and prognosis of hyperdynamic left ventricular ejection fraction in critically ill patients with sepsis.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Hyperdynamic left ventricular ejection fraction as a predictor of mortality in intensive care unit patients with septic shock.
    Hedia DSM, Mahmoud HO, AbdelFattah AM, AbdelSalam EH, et al · · 2026 · PMID 41319356 · DOI 10.1016/j.hrtlng.2025.11.015

Verify or expand the search:

Other trials of Transthoracic echocardiography

Trials testing the same drug.

Other Ain Shams University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06993948.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing